

Research Paper

International Journal of Medical Sciences

2024; 21(11): 2119-2126. doi: 10.7150/ijms.95430

The Association between Percentage of Mean Arterial Pressure and Long-Term Mortality in Acute Myocardial Infarction Patients: An Observational Cohort Study

Yi-Hsueh Liu, MD^{1,2,3}; Wei-Chung Tsai, MD^{1,3}; Nai-Yu Chi, MD¹; Ching-Tang Chang, MD¹; Wen-Hsien Lee, MD, PhD^{1,2,3}; Chun-Yuan Chu, MD^{1,3}; Tsung-Hsien Lin, MD, PhD^{1,3}; Sheng-Hsiung Sheu, MD^{1,3}; Ho-Ming Su, MD^{1,2,3}; Po-Chao Hsu, MD, PhD^{1,3}

1. Division of Cardiology, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan.

2. Department of Internal Medicine, Kaohsiung Municipal Siaogang Hospital, Kaohsiung, Taiwan.

3. Faculty of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan.

Corresponding authors: Po-Chao Hsu, MD, PhD, Division of Cardiology, Department of Internal Medicine, Kaohsiung Medical University Hospital, 100 Tzyou 1st Road, Kaohsiung 807, Taiwan; Tel.: +886-7-3121101 ext 7738, Fax: +886-7-3234845; E-mail: pochao.hsu@gmail.com & Ho-Ming Su, MD, Department of Internal Medicine, Kaohsiung Municipal Siaogang Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan, 482 Shan-Ming Rd., Siaogang Dist., 812 Kaohsiung, Taiwan; Tel.: 886-7-8036783 - 3441, Fax: 886-7- 8063346; E-mail: cobeshm@seed.net.tw.

© The author(s). This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.

Received: 2024.02.17; Accepted: 2024.08.04; Published: 2024.08.12

Abstract

Background: Acute myocardial infarction (AMI) is a critical cardiovascular disease with high morbidity and mortality. Identifying practical parameters for predicting long-term mortality is crucial in this patient group. The percentage of mean arterial pressure (%MAP) is a useful parameter used to assess peripheral artery disease. It can be easily calculated from ankle pulse volume recording. Previous studies have shown that %MAP is a useful predictor of all-cause mortality in specific populations, but its relationship with mortality in AMI patients is unclear.

Methods: In this observational cohort study, 191 AMI patients were enrolled between November 2003 and September 2004. Ankle-brachial index (ABI) and %MAP were measured using an ABI-form device. All-cause and cardiovascular mortality data were collected from a national registry until December 2018. Cox proportional hazards model and Kaplan-Meier survival plot were used to analyze the association between %MAP and long-term mortality in AMI patients.

Results: The median follow-up to mortality was 65 months. There were 130 overall and 36 cardiovascular deaths. High %MAP was associated with increased overall mortality after multivariable analysis (HR = 1.062; 95% CI: 1.017-1.109; p = 0.006). However, high % MAP was only associated with cardiovascular mortality in the univariable analysis but became insignificant after the multivariable analysis.

Conclusions: In conclusion, this study is the first to evaluate the usefulness of %MAP in predicting long-term mortality in AMI patients. Our study shows that %MAP might be an independent predictor of long-term overall mortality in AMI patients and has better predictive power than ABI.

Keywords: acute myocardial infarction; cardiovascular; mortality; percentage of mean arterial pressure; ankle-brachial index

Introduction

Acute myocardial infarction (AMI) is a major cause of mortality worldwide and can result in significant health-related burden [1]. In Taiwan, cardiovascular disease (CVD) has been the second leading cause of mortality since 2010, and AMI is the most severe form of CVD [2]. Patients in Taiwan with ST-segment elevation myocardial infarction (STEMI) and Non-ST-segment elevation myocardial infarction (NSTEMI) had a 1-year mortality rate of 6.1% and 10.1%, respectively [3]. Peripheral artery disease (PAD) is a coexisting condition that increases cardiovascular risk and mortality in patients with AMI [4, 5]. However, it is under-diagnosed as 40%-50% of patients with PAD are asymptomatic [6,

7].

The ankle-brachial index (ABI), the ratio of ankle-to-brachial systolic blood pressure, is a commonly used non-invasive diagnostic tool for PAD [8, 9]. The current guidelines recommend that resting ABI results be classified as abnormal (ABI ≤ 0.90), borderline (ABI 0.91-0.99), normal (1.00-1.40), or noncompressible (ABI >1.40) [8, 9]. Moreover, the ABI has been shown to be a useful predictor for risk of cardiovascular disease events and all-cause mortality [10]. However, the sensitivity of ABI to detect PAD is limited in patients with diabetes or chronic kidney disease (CKD) because calcification of the arteries can result in vascular inability to be compressed. [11-13]. Ultimately, finding a reliable and user-friendly tool is essential to aid in the early detection of subclinical PAD and prevent further cardiovascular events.

The percentage of mean arterial pressure (%MAP) is a convenient index for screening for PAD. It can be calculated from a pulse volume recording at the ankle and automatically reported by the ABI-measuring machine. The %MAP is calculated as the percentage of the area under the pulse waveform relative to the area of the rectangle that encloses the pulse waveform [14-16]. The %MAP indicates a flattened arterial wave and can serve as a diagnostic criterion for PAD in patients with falsely elevated ABI values due to noncompressible vessels [16, 17]. Combining the ABI and the %MAP can help improve the diagnostic sensitivity of PAD [18, 19]. In a previous study primarily composed of individuals with diabetes and the elderly, a higher %MAP was found to correlate with increased mortality risk among participants with normal range ABI values [14]. The main value of %MAP may be that it is not affected by noncompressible arteries. Even within the normal range of ABI values, patients with a higher %MAP may better reflect the actual characteristics of arterial occlusion and arteriosclerosis. In addition, %MAP is also a useful predictor of all-cause mortality in specific populations, including diabetes and hemodialysis patients [20, 21]. However, the relationship between %MAP and mortality has not yet been assessed in participants with AMI. Therefore, the present study aims to determine whether the %MAP predicts long-term cardiovascular and overall mortality in AMI patients.

Materials and Methods

Study population and design

This observational cohort study enrolled patients diagnosed with AMI between November 2003 and September 2004 in our cardiac care unit. Both STEMI and NSTEMI patients were included in the study, with the minimum age requirement being 20 years. The authors had access to information that could identify individual participants during or after data collection. Patients were excluded from the study if they had unstable hemodynamic status, atrial fibrillation, limb amputation, or missing data on four-limb blood pressures, ABI, or %MAP. Finally, the study included a total of 191 AMI patients. All cause and cardiovascular mortality data were obtained from the Collaboration Center of Health Information Application, Ministry of Health and Welfare, Executive Yuan, Taiwan, and were collected up to December 2018. The medical information and data were accessed for research purposes on February 25, 2020.

Ethics statement

The research protocol was approved by the institutional review board (IRB) committee of Kaohsiung Medical University (KMUHIRB-E(I)-20190258). All patients provided written informed consent during the first day of admission, and all clinical investigations adhered to the principles outlined in the Declaration of Helsinki.

Assessment of ABI, %MAP, and four limb blood pressures by ABI-form device

The ABI, %MAP and blood pressures in all four limbs were measured using an ABI-form device (VP1000; Colin Co. Ltd., Komaki, Japan) that employs an oscillometric method to measure blood pressure in both arms and ankles simultaneously after resting in a supine position for at least 5 minutes [22, 23]. Cuffs were placed tightly around the upper arms and ankles for occlusion and monitoring purposes without accessing blood. The ABI of each leg was determined by dividing the ankle systolic blood pressure by the higher brachial systolic blood pressure, and the lower of the two ABI values was used for data analysis. The %MAP was automatically determined from the pulse volume recordings by using the following formula [16]:

% MAP (%) =

area enclosed with a pulse volume curve and its initial base \div (time length of a pulse $\,\times\,$

height of a pulse volume amplitude) \times 100)

The higher %MAP between both legs was selected for analysis. The ABI-form device measurement was performed once within 24 hours of admission to the cardiac care unit for each patient.

Collection of demographic and medical data

Demographic and medical information, such as age, gender, and comorbidities like dyslipidemia,

diabetes, and hypertension, were obtained from the patients' medical records.

Statistical analysis

Statistical analyses were conducted using SPSS 22.0 software (SPSS, Chicago, IL, USA). The data were presented as mean ± standard deviation, percentage, or median (25th-75th percentile) for the follow-up period. The independent samples t-test and Chi-square test were used to compare continuous and categorical variables between groups, respectively. In our study, we performed both univariable and multivariable Cox proportional hazards regression analyses to determine the predictors of overall and cardiovascular mortality. In the univariable analysis, each variable was analyzed independently to assess its association with the outcomes. Variables that were found to be significant in the univariable analysis (p < p0.05) were then included in the multivariable analysis to control for potential confounders and assess the independent effect of each variable on mortality. Kaplan-Meier survival plot was calculated from baseline to time of mortality events. All tests were 2-sided and P value less than 0.05 was considered statistically significant.

Adjustment for confounders

In our multivariable Cox proportional hazards regression models, we adjusted for several potential confounders, including age, gender, hypertension, heart rate, BMI, LVEF, ABI, and %MAP. These factors were selected based on their known associations with cardiovascular outcomes and mortality in the literature. The theoretical basis for these adjustments is to control for variables that could influence both the exposure (%MAP) and the outcomes (overall and cardiovascular mortality), thus providing a clearer understanding of the independent effect of %MAP. In addition, only significant variables in the univariate analysis were included in the multivariate analysis.

Results

Of the 191 subjects (139 males and 52 females) included in this study, the mean age of 65.8 ± 13.5 years for our study population is consistent with the reported average age for patients with AMI in Taiwan [24]. Among them, 36 patients had STEMI while 155 had NSTEMI. The median follow-up period for mortality was 65 months, with a range of 6 to 174 months (25th–75th percentile). There were 130 and 36 patients documented as all cause and cardiovascular mortality, respectively.

Table 1 shows a comparison of the clinicalcharacteristics between survivors and non-survivors.Compared to the survivors, the non-survivors were

older, had a higher prevalence of female gender, higher prevalence rates of hypertension, higher heart rate, higher body mass index (BMI), lower left ventricular ejection fraction (LVEF), lower ABI (0.91 \pm 0.22 versus 1.03 \pm 0.11, p < 0.001), and higher %MAP (44.1 \pm 7.8 versus 36.6 \pm 5.0, p < 0.001).

Table 1. Comparison of baseline characteristics betweenSurvivors and Non-survivors

Characteristics	Survivors (n =61)	Non-survivors (<i>n</i> =130)	<i>p</i> value	All patients (<i>n</i> = 191)
Age (years)	55.3 ± 11.6	70.7 ± 11.5	< 0.001	65.8 ± 13.5
Male gender (%)	83.6	67.7	0.013	72.8
Hypertension (%)	27.9	47.7	0.007	41.4
Diabetes mellitus (%)	24.6	28.5	0.578	27.2
Dyslipidemia (%)	69.2	64.7	0.683	66.0
STEMI (%)	21.3	17.7	0.553	18.9
NSTEMI (%)	78.7	82.3	0.553	71.1
Heart rate (beat/min)	73.8 ± 14.4	81.2 ± 17.8	0.003	78.8 ± 17.1
Body mass index (kg/m ²)	25.6 ± 3.2	23.6 ± 3.9	0.001	24.2 ± 3.8
LVEF (%)	63.7 ± 12.5	55.7 ± 16.2	0.002	58.9 ± 15.3
Ankle brachial index	1.03 ± 0.11	0.91 ± 0.22	< 0.001	0.95 ± 0.20
%MAP	36.6 ± 5.0	44.1 ± 7.8	< 0.001	41.7 ± 7.8

Abbreviations: STEMI, ST-segment elevation myocardial infarction; NSTEMI, non-ST elevation myocardial infarction; LVEF, left ventricular ejection fraction; %MAP, percentage of mean arterial pressure

Table 2 shows the predictors of overall mortality using Cox proportional hazards model in the univariable and multivariable analysis. In our univariable analysis, older age, female gender, presence of hypertension, increased heart rate, lower body mass index, lower LVEF, lower ABI, and higher %MAP were significant predictors of overall mortality. After multivariable analysis adjusted for age, gender, hypertension, heart rate, BMI, LVEF, ABI, and %MAP (significant variables in univariable analysis), only age (hazard ratio [HR] = 1.047; 95% confidence interval [CI]: 1.022-1.073; p < 0.001), LVEF (HR = 0.981; 95% CI: 0.965-0.998; p = 0.025), and %MAP (HR = 1.062; 95% CI: 1.017-1.109; p = 0.006) were significantly associated with overall mortality. Lower ABI became insignificant after multivariable analysis (p = 0.712).

Table 3 shows the predictors of cardiovascular mortality using Cox proportional hazards model in the univariable and multivariable analysis. In our univariable analysis, older age, female gender, higher percentage of hypertension, increased heart rate, lower ABI, and higher %MAP were significant of cardiovascular mortality. predictors After multivariable analysis adjusted for age, gender, hypertension, heart rate, ABI and %MAP (significant variable in univariable analysis), only age (HR = 1.038; 95% CI: 1.001-1.076; *p* =0.043) was significantly associated with cardiovascular mortality. Lower ABI (p = 0.652).and higher %MAP (p = 0.990) became insignificant after multivariable analysis.

The optimal cut-off vales of %MAP and for the prediction of overall mortality and cardiovascular mortality have not been established in patients with AMI. Therefore, we used the mean value of %MAP as the cut-off, resulting in 85 patients with %MAP greater than the mean value (%MAP>41.7%) and 105 patients with %MAP less than or equal to the mean value (%MAP≤41.7%). Figure 1 illustrates the adjusted Kaplan-Meier curves of %MAP above the median versus below the median for overall mortality-free survival (log-rank p < 0.001). Figure 2 shows the adjusted Kaplan-Meier curves of %MAP above the median versus below the median for overall mortality-free survival (log-rank p < 0.001). Figure 2 shows the adjusted Kaplan-Meier curves of %MAP above the median versus below the median for cardiovascular mortality-free survival (log-rank p = 0.005).

 Table 2. Predictors of overall mortality using Cox proportional hazards model by univariable and multivariable analysis

Parameter	Univariable analysis		Multivariable analysis				
	HR (95% CI)	P	HR (95% CI)	P			
Age (Per 1 year)	1.074 (1.057-1.091)	< 0.001	1.047 (1.022-1.073)	< 0.001			
Gender (Male vs.	0.602 (0.416-0.872)	0.007	1.113 (0.618-2.004)	0.721			
Female)							
Hypertension (Yes	1.505 (1.066-2.125)	0.020	0.950 (0.580-1.558)	0.840			
vs. No)							
Diabetes mellitus	1.143 (0.778-1.680)	0.496	-	-			
(Yes vs. No)							
Dyslipidemia (Yes	0.773 (0.469-1.274)	0.312	-	-			
vs. No)							
STEMI (Yes vs. No)	0.881 (0.561-1.384)	0.583	-	-			
Heart rate (Per	1.018 (1.008-1.028)	< 0.001	1.011 (0.996-1.026)	0.162			
beat/min)							
Body mass index	0.897 (0.853-0.944)	< 0.001	0.966 (0.904-1.031)	0.296			
(Per 1kg/m ²)							
LVEF (Per 1%)	0.983 (0.969-0.997)	0.016	0.981 (0.965-0.998)	0.025			
Ankle brachial	0.073 (0.031-0.170)	< 0.001	1.382 (0.247-7.719)	0.712			
index (Per 1SD)							
%MAP (Per 1SD)	1.087 (1.064-1.110)	< 0.001	1.062 (1.017-1.109)	0.006			
HR: hazard ratio: CI: confidence interval: SD: standard deviation: other							

HR: hazard ratio; CI: confidence interval; SD: standard deviation; other abbreviations as in Table 1.

 Table 3. Predictors of cardiovascular mortality using Cox

 proportional hazards model by univariable and multivariable

 analysis

Parameter	Univariable analys	is	Multivariable analysis		
	HR (95% CI)	Р	HR (95% CI)	Р	
Age (Per 1 year)	1.051 (1.021-1.082)	0.001	1.038 (1.001-1.076))	0.043	
Gender (Male vs.	0.462 (0.236-0.908)	0.025	0.753 (0.342-1.657)	0.481	
Female)					
Hypertension (Yes vs.	2.592 (1.323-5.077)	0.005	1.717 (0.837-3.523)	0.140	
No)					
Diabetes mellitus (Yes	1.150 (0.554-2.387)	0.707	-	-	
vs. No)					
Dyslipidemia (Yes vs.	0.867 (0.349-2.151)	0.758	-	-	
No)					
STEMI (Yes vs. No)	1.005 (0.440-2.297)	0.990	-	-	
Heart rate (Per	1.019 (1.001-1.038)	0.040	1.016 (0.996 - 1.036)	0.124	
1beat/min)					
Body mass index (Per	0.955 (0.869-1.049)	0.337	-	-	
1kg/m²)					
LVEF (Per 1%)	0.978 (0.950-1.006)	0.126	-	-	
Ankle brachial index	0.160 (0.030-0.846)	0.031	0.599 (0.065-5.548)	0.652	
(Per 1SD)					
%MAP (Per 1SD)	1.051 (1.007-1.097)	0.023	1.000 (0.934-1.072)	0.990	

HR: hazard ratio; CI: confidence interval; SD: standard deviation; other abbreviations as in Table 1.

Discussion

The aim of our study was to assess the predictive value of %MAP for overall and cardiovascular mortality in AMI patients. Our study vielded several key findings. First, higher %MAP was found to be associated with an increased risk of overall mortality in both univariable and multivariable analysis. Second, in univariable analysis, higher %MAP was associated with increased cardiovascular also although this association became mortality, insignificant in multivariable analysis. Third, while ABI was found to be associated with increased total and cardiovascular mortality in univariable analysis, it lost its significance when multivariable analyses were added to %MAP. Finally, %MAP demonstrated better predictive value than conventional parameters, such as ABI and LVEF, for overall mortality prediction in AMI patients.

Over the past decade, the prognosis of patients with AMI has improved due to the adoption of guideline-recommended treatment methods such as early vascular revascularization, anti-thrombotic therapy, and other secondary prevention measures [25-27]. Most data focus on events and predictors within the first year after AMI [28-30], and there is still little understanding of which risk factors can influence long-term cardiovascular events and all-cause mortality after the onset of AMI [31, 32]. There are many traditional risk factors that have been found to be associated with short-term and long-term cardiovascular prognosis, such as age, gender, renal impairment, diabetes, heart rate, BMI and LVEF [28, 29, 31-33]. Our study also found that these traditional factors affect long-term all-cause mortality, in line with previous studies.

Patients with AMI who also have clinical PAD are at a higher risk of mortality during their index hospitalization [34] as well as during long-term follow-up [5, 35]. Previous studies reported that both subclinical and clinical PAD are associated with a poor prognosis in patients with AMI, indicating that routine ABI testing could be prognostically significant regardless of PAD symptoms [4, 36]. The association between ABI and mortality has a U-shaped curve rather than a linear correlation [37, 38]. In patients with AMI, those with low ABI have a higher mortality rate [4, 5]. However, the predictive ability of ABI varies among different comorbid populations. Low ABI was linked to mortality in both individuals with and without diabetes in the REACH registry, while the association with high ABI was only apparent in patients with diabetes [39]. However, in certain patient populations, such as those with diabetes mellitus or CKD, the ABI may be false elevated due to vascular calcification [11-13, 40]. This could affect the diagnostic accuracy and consequently the accuracy of the ABI as a prognostic factor. In our study, low ABI was found to be associated with both overall and cardiovascular mortality in univariable analysis, but this association was not statistically significant in the multivariable analysis.

The ABI-form (VP 1000; Colin Co Ltd, Komaki, Japan) is a clinical device that utilizes an automated oscillometric method to measure blood pressures in




Figure 1. Adjusted Kaplan–Meier curves of %MAP above the median versus below the median for overall mortality-free survival (log-rank p<0.001).




Figure 2. Adjusted Kaplan-Meier curves of %MAP above the median versus below the median for cardiovascular mortality-free survival (log-rank p=0.005).

all four limbs and record pulse waves simultaneously and automatically [16]. This device simultaneously four limbs recorded blood pressure, ABI, electrocardiogram, phonocardiogram and % MAP. Pulse volume recording is a viable alternative tool for diagnosing PAD with calcified vessels [41], and its main value may be that it is unaffected by the presence of incompressible arteries [17]. This is achieved by using pneumatic cuffs to inject a standard volume of air and occlude the venous circulation to solely detect volume changes related to arterial circulation, as translated by the transducer into a pulsatile pressure waveform [42]. Li et al. were the first to apply ankle %MAP to predict mortality and found that a high %MAP obtained from pulse volume recording was a strong predictor of all-cause mortality in participants with an ABI value in the range of 0.9-1.3, after adjusting for various confounding factors [14]. Lee et al. reported that increased %MAP and %MAP > 50% were significant predictors of total mortality, while %MAP > 50% was a predictor of cardiovascular mortality. These findings suggest that assessing %MAP from pulse volume recording at the ankle could be a useful tool for identifying high-risk hemodialysis patients for poor prognosis [21]. For type 2 diabetes patient, Li et a. also found that the %MAP in combination with the ABI can improve the prediction of mortality. The study retrospectively collected data from 5569 patients and found that the combination of ABI and %MAP was more effective than ABI alone in predicting mortality. In multivariate analysis, the highest risk of mortality was seen in patients with ABI \leq 0.90 and %MAP > 45%. Therefore, using %MAP in conjunction with ABI could improve the prediction of all-cause mortality in patients with type 2 diabetes [20].

In our present study, high %MAP was found to be significantly associated with long-term overall mortality in both univariable and multivariable analyses among patients with AMI. Although a significant difference was observed in the association between high %MAP and long-term cardiovascular mortality in patients with AMI in univariable analyses, such a difference was not seen in multivariable analyses after adjusting for various confounding factors. In our analysis of the Kaplan Meier survival curve, we also found that AMI patients with a %MAP greater than the mean value (41.7 %) had a higher overall mortality. Therefore, in our study, we found that among patients with AMI, %MAP was a potential parameter that could be used as a predictor of overall mortality.

Study limitations

There are several limitations to this study. First, the study generality was limited because the study included only patients from the intensive care unit of single medical center in southern Taiwan. Second, we did not assess the association of peripheral arterial occlusive disease with %MAP in the image study. Third, the sample size of our study was not very large, but the follow-up period was long, up to 181 months. Fourth, our study was missing many cardiovascular risk factors from the characteristics at baseline, such as continuous blood pressure, LDL, and glucose values at the baseline followed by smoking history and drug history. Due to incomplete data, we did not adjust for many biochemical markers and cardiovascular risk factors in our univariate and multivariate analyses. This is because at our hospital, detailed medical records of patients are not available if they do not return to our hospital for more than 10 years. Fifth, we have solely analyzed outcomes such as cardiovascular mortality and overall mortality; however, we lack relevant data on cardiovascular morbidity, major adverse cardiovascular events, and stroke to thoroughly evaluate the outcomes. Sixth, in this study, men and women were analyzed together due to the limited sample size. We acknowledge that gender differences in cardiovascular risk factors could influence the outcomes. Future studies with larger sample sizes will include sex-stratified analyses or interaction tests to explore gender-specific effects. Finally, we conducted a post hoc power analysis to determine the adequacy of our sample size. The power analysis indicated that our study had sufficient power to detect significant associations between %MAP and overall mortality but might be underpowered for some subgroup analyses, such as cardiovascular mortality and sex-stratified analyses. This limitation underscores the need for larger sample sizes in future studies to confirm our findings and explore additional outcomes.

Conclusions

Our study is the first study to evaluate the usefulness of %MAP in AMI patients for prediction of long-term overall and cardiovascular mortality. Our study showed %MAP might be used as a potential parameter to predict long-term overall mortality among AMI patients. In addition, it also has a better additive predictive value for long-term mortality than ABI and LVEF in AMI patients. Thus, utilizing %MAP as a simple screening tool in AMI patients may assist clinicians in identifying individuals at high risk of increased mortality.

Abbreviations

AMI: acute myocardial infarction; CVD: cardiovascular disease; STEMI: ST-segment elevation myocardial infarction; NSTEMI: Non-ST-segment elevation myocardial infarction; PAD: Peripheral artery disease; ABI: ankle-brachial index; CKD: chronic kidney disease; %MAP: percentage of mean arterial pressure; BMI: body mass index; LVEF: left ventricular ejection fraction.

Acknowledgements

Mortality data were provided by the Collaboration Center of Health Information Application, Ministry of Health and Welfare, Executive Yuan.

Data availability

The datasets used and/or analyzed during the current study available from the corresponding author on reasonable request.

Author contributions

Y-HL and P-CH prepared the main manuscript text. W-CT, N-YC and C-TC were responsible for the main statistics and analyses. W-HL and C-YC were responsible for the collection of patient information. T-HL and S-HS checked the statistical methods and results. H-MS and P-CH made major contributions to the study design and review of the manuscript. All the authors reviewed the manuscript.

Competing Interests

The authors have declared that no competing interest exists.

References

- Roth GA, Mensah GA, Johnson CO, Addolorato G, Ammirati E, Baddour LM, et al. Global Burden of Cardiovascular Diseases and Risk Factors, 1990-2019: Update From the GBD 2019 Study. J Am Coll Cardiol. 2020; 76: 2982-3021.
- Ministry of Health and Welfare T. Cause of Death Statistics Datasets. Taiwan: Ministry of Health and Welfare, Taiwan; 2023.
- Chu CY, Lin TH, Lai WT. The Management and Prognostic Factors of Acute Coronary Syndrome: Evidence from the Taiwan Acute Coronary Syndrome Full Spectrum Registry. Acta Cardiol Sin. 2017; 33: 329-38.
- Berkovitch A, Iakobishvili Z, Fuchs S, Atar S, Braver O, Eisen A, et al. Peripheral artery disease, abnormal ankle-brachial index, and prognosis in patients with acute coronary syndrome. Front Cardiovasc Med. 2022; 9: 902615.
- Al-Zakwani I, Al Siyabi E, Alrawahi N, Al-Mulla A, Alnaeemi A, Shehab A, et al. Association between Peripheral Artery Disease and Major Adverse Cardiovascular Events in Patients with Acute Coronary Syndrome: Findings from the Gulf COAST Registry. Med Princ Pract. 2019; 28: 410-7.
- Aday AW, Matsushita K. Epidemiology of Peripheral Artery Disease and Polyvascular Disease. Circ Res. 2021; 128: 1818-32.
- Shu J, Santulli G. Update on peripheral artery disease: Epidemiology and evidence-based facts. Atherosclerosis. 2018; 275: 379-81.
- Gerhard-Herman MD, Gornik HL, Barrett C, Barshes NR, Corriere MA, Drachman DE, et al. 2016 AHA/ACC Guideline on the Management of Patients With Lower Extremity Peripheral Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2017; 135: e726-e79.
- Aboyans V, Ricco JB, Bartelink MEL, Bjorck M, Brodmann M, Cohnert T, et al. 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS): Document covering atherosclerotic disease of extracranial carotid and

vertebral, mesenteric, renal, upper and lower extremity arteriesEndorsed by: the European Stroke Organization (ESO)The Task Force for the Diagnosis and Treatment of Peripheral Arterial Diseases of the European Society of Cardiology (ESC) and of the European Society for Vascular Surgery (ESVS). Eur Heart J. 2018; 39: 763-816.

- Yokoyama H, Sone H, Honjo J, Okizaki S, Yamada D, Shudo R, et al. Relationship between a low ankle brachial index and all-cause death and cardiovascular events in subjects with and without diabetes. J Atheroscler Thromb. 2014; 21: 574-81.
- Emanuele MA, Buchanan BJ, Abraira C. Elevated leg systolic pressures and arterial calcification in diabetic occlusive vascular disease. Diabetes Care. 1981; 4: 289-92.
- Ix JH, Katz R, De Boer IH, Kestenbaum BR, Allison MA, Siscovick DS, et al. Association of chronic kidney disease with the spectrum of ankle brachial index the CHS (Cardiovascular Health Study). J Am Coll Cardiol. 2009; 54: 1176-84.
- AbuRahma AF, Adams E, AbuRahma J, Mata LA, Dean LS, Caron C, et al. Critical analysis and limitations of resting ankle-brachial index in the diagnosis of symptomatic peripheral arterial disease patients and the role of diabetes mellitus and chronic kidney disease. J Vasc Surg. 2020; 71: 937-45.
- Li YH, Lin SY, Sheu WH, Lee IT. Relationship between percentage of mean arterial pressure at the ankle and mortality in participants with normal ankle-brachial index: an observational study. BMJ Open. 2016; 6: e010540.
- Arita Y, Ogasawara N, Hasegawa S. Correlations Between the Ankle-Brachial Index, Percentage of Mean Arterial Pressure, and Upstroke Time for Endovascular Treatment. Cardiol Res. 2020; 11: 392-7.
- Watanabe Y, Masaki H, Yunoki Y, Tabuchi A, Morita I, Mohri S, et al. Ankle-Brachial Index, Toe-Brachial Index, and Pulse Volume Recording in Healthy Young Adults. Ann Vasc Dis. 2015; 8: 227-35.
- Shirasu T, Hoshina K, Akagi D, Miyahara T, Yamamoto K, Watanabe T. Pulse volume recordings to identify falsely elevated ankle brachial index. Asian Cardiovasc Thorac Ann. 2016; 24: 517-22.
- Lin HW, Lee IT. Combination of the ankle-brachial index and percentage of mean arterial pressure to improve diagnostic sensitivity for peripheral artery disease: An observational study. Medicine (Baltimore). 2018; 97: e12644.
- Hashimoto T, Ichihashi S, Iwakoshi S, Kichikawa K. Combination of pulse volume recording (PVR) parameters and ankle-brachial index (ABI) improves diagnostic accuracy for peripheral arterial disease compared with ABI alone. Hypertens Res. 2016; 39: 430-4.
- Li YH, Sheu WH, Lee IT. Use of the ankle-brachial index combined with the percentage of mean arterial pressure at the ankle to improve prediction of all-cause mortality in type 2 diabetes mellitus: an observational study. Cardiovasc Diabetol. 2020; 19: 173.
- Lee WH, Hsu PC, Huang JC, Chen YC, Chen SC, Wu PY, et al. Association of Pulse Volume Recording at Ankle with Total and Cardiovascular Mortality in Hemodialysis Patients. J Clin Med. 2019; 8: 2045.
- Yamashina A, Tomiyama H, Takeda K, Tsuda H, Arai T, Hirose K, et al. Validity, reproducibility, and clinical significance of noninvasive brachial-ankle pulse wave velocity measurement. Hypertens Res. 2002; 25: 359-64.
- Tomiyama H, Yamashina A, Arai T, Hirose K, Koji Y, Chikamori T, et al. Influences of age and gender on results of noninvasive brachial-ankle pulse wave velocity measurement--a survey of 12517 subjects. Atherosclerosis. 2003; 166: 303-9.
- Chiang FT, Shyu KG, Wu CJ, Mar GY, Hou CJ, Li AH, et al. Predictors of 1-year outcomes in the Taiwan Acute Coronary Syndrome Full Spectrum Registry. J Formos Med Assoc. 2014; 113: 794-802.
- Rossello X, Pocock SJ, Julian DG. Long-Term Use of Cardiovascular Drugs: Challenges for Research and for Patient Care. J Am Coll Cardiol. 2015; 66: 1273-85.
- Collet JP, Thiele H, Barbato E, Barthelemy O, Bauersachs J, Bhatt DL, et al. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J. 2021; 42: 1289-367.
- 27. Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2018; 39: 119-77.
- Constantinides SS, Gieowarsingh S, Halim M, Been M, Shiu MF. Predictors of mortality in patients with acute coronary syndrome undergoing percutaneous coronary intervention. Heart. 2003; 89: 1245-6.
- Granger CB, Goldberg RJ, Dabbous O, Pieper KS, Eagle KA, Cannon CP, et al. Predictors of hospital mortality in the global registry of acute coronary events. Arch Intern Med. 2003; 163: 2345-53.
- Boersma E, Pieper KS, Steyerberg EW, Wilcox RG, Chang WC, Lee KL, et al. Predictors of outcome in patients with acute coronary syndromes without persistent ST-segment elevation. Results from an international trial of 9461 patients. The PURSUIT Investigators. Circulation. 2000; 101: 2557-67.
- Jernberg T, Hasvold P, Henriksson M, Hjelm H, Thuresson M, Janzon M. Cardiovascular risk in post-myocardial infarction patients: nationwide real world data demonstrate the importance of a long-term perspective. Eur Heart J. 2015; 36: 1163-70.

- 32. Rossello X, Bueno H, Pocock SJ, Van de Werf F, Danchin N, Annemans L, et al. Predictors of all-cause mortality and ischemic events within and beyond 1 year after an acute coronary syndrome: Results from the EPICOR registry. Clin Cardiol. 2019; 42: 111-9.
- Pocock SJ, Huo Y, Van de Werf F, Newsome S, Chin CT, Vega AM, et al. Predicting two-year mortality from discharge after acute coronary syndrome: An internationally-based risk score. Eur Heart J Acute Cardiovasc Care. 2019; 8: 727-37.
- Froehlich JB, Mukherjee D, Avezum A, Budaj A, Kline-Rogers EM, Lopez-Sendon J, et al. Association of peripheral artery disease with treatment and outcomes in acute coronary syndromes. The Global Registry of Acute Coronary Events (GRACE). Am Heart J. 2006; 151: 1123-8.
- Spencer FA, Lessard D, Doubeni C, Yarzebski J, Gore JM, Goldberg RJ. Treatment practices and outcomes of patients with established peripheral arterial disease hospitalized with acute myocardial infarction in a community setting. Am Heart J. 2007; 153: 140-6.
- Morillas P, Quiles J, Cordero A, Guindo J, Soria F, Mazon P, et al. Impact of clinical and subclinical peripheral arterial disease in mid-term prognosis of patients with acute coronary syndrome. Am J Cardiol. 2009; 104: 1494-8.
- Suominen V, Uurto I, Saarinen J, Venermo M, Salenius J. PAD as a risk factor for mortality among patients with elevated ABI--a clinical study. Eur J Vasc Endovasc Surg. 2010; 39: 316-22.
- Resnick HE, Lindsay RS, McDermott MM, Devereux RB, Jones KL, Fabsitz RR, et al. Relationship of high and low ankle brachial index to all-cause and cardiovascular disease mortality: the Strong Heart Study. Circulation. 2004; 109: 733-9.
- Potier L, Roussel R, Labreuche J, Marre M, Cacoub P, Rother J, et al. Interaction between diabetes and a high ankle-brachial index on mortality risk. Eur J Prev Cardiol. 2015; 22: 615-21.
- Potier L, Halbron M, Bouilloud F, Dadon M, Le Doeuff J, Ha Van G, et al. Ankle-to-brachial ratio index underestimates the prevalence of peripheral occlusive disease in diabetic patients at high risk for arterial disease. Diabetes Care. 2009; 32: e44.
- Gerhard-Herman MD, Gornik HL, Barrett C, Barshes NR, Corriere MA, Drachman DE, et al. 2016 AHA/ACC Guideline on the Management of Patients With Lower Extremity Peripheral Artery Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2017; 135: e686-e725.
- 42. Gerhard-Herman M, Gardin JM, Jaff M, Mohler E, Roman M, Naqvi TZ, et al. Guidelines for noninvasive vascular laboratory testing: a report from the American Society of Echocardiography and the Society of Vascular Medicine and Biology. J Am Soc Echocardiogr. 2006; 19: 955-72.